Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Ibudilast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 154Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MediciNova Updates Ph 2/3 COMBAT-ALS Trial at ALS/MND Symposium
    MediciNova Updates Ph 2/3 COMBAT-ALS Trial at ALS/MND Symposium

    06 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/05/2992777/7767/en/MediciNova-Presents-Study-Update-and-Interim-Analysis-of-Phase-2-3-Clinical-Trial-of-MN-166-ibudilast-in-ALS-COMBAT-ALS-Clinical-Trial-at-the-35th-International-Symposium-on-ALS-MN.html

    GLOBENEWSWIRE
    06 Dec 2024
    Share Share
    MediciNova's MN-166 Abstract Accepted For Poster Presentation
    MediciNova's MN-166 Abstract Accepted For Poster Presentation

    09 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/09/2943304/7767/en/MediciNova-Announces-Abstract-Regarding-MN-166-ibudilast-in-COMBAT-ALS-Clinical-Trial-Accepted-for-Poster-Presentation-at-the-35th-International-Symposium-on-ALS-MND.html

    GLOBENEWSWIRE
    09 Sep 2024
    Share Share
    MediciNova's MN-166 in COMBAT-ALS Study to Present at NEALS 2024 Meeting
    MediciNova's MN-166 in COMBAT-ALS Study to Present at NEALS 2024 Meeting

    03 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/03/2940160/7767/en/MediciNova-Announces-Acceptance-of-Abstract-Regarding-MN-166-ibudilast-in-COMBAT-ALS-Clinical-Trial-for-Presentation-at-the-2024-Annual-NEALS-Northeast-Amyotrophic-Lateral-Sclerosi.html

    GLOBENEWSWIRE
    03 Sep 2024
    Share Share
    MediciNova Receives Patent Notice for MN-166 in Post-COVID Condition
    MediciNova Receives Patent Notice for MN-166 in Post-COVID Condition

    29 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/29/2938199/7767/en/MediciNova-Receives-Notice-of-Allowance-from-United-States-Patent-and-Trademark-Office-for-New-Patent-Covering-MN-166-ibudilast-for-the-Post-COVID-Condition.html

    GLOBENEWSWIRE
    29 Aug 2024
    Share Share
    MediciNova's MN-166 Glioblastoma Data At ASCO 2024
    MediciNova's MN-166 Glioblastoma Data At ASCO 2024

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892064/7767/en/MediciNova-Announces-Data-from-Phase-1b-2a-Clinical-Trial-of-MN-166-ibudilast-in-Glioblastoma-Patients-at-the-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting-2024.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    MediciNova Allowed Patent Covers MN-166 Eye Cancer Metastasis Prevention
    MediciNova Allowed Patent Covers MN-166 Eye Cancer Metastasis Prevention

    20 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/20/2884704/7767/en/MediciNova-Receives-Notice-of-Allowance-for-New-Patent-Covering-MN-166-ibudilast-for-the-Prevention-of-Metastasis-of-Eye-Cancer.html

    GLOBENEWSWIRE
    20 May 2024
    Share Share